Idorsia Ltd (SWX:IDIA)

Market Cap	889.08M +451.6%
Revenue (ttm)	220.58M +96.1%
Net Income	-111.70M
EPS	-0.52
Shares Out	251.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,094,663
Average Volume	1,712,526
Open	3.900
Previous Close	3.890
Day's Range	3.535 - 3.940
52-Week Range	0.851 - 4.850
Beta	1.75
RSI	50.56
Earnings Date	Feb 26, 2026

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: IDIA

Financial Performance

In 2025, Idorsia's revenue was 220.58 million, an increase of 96.06% compared to the previous year's 112.51 million. Losses were -111.70 million, -57.65% less than in 2024.